UCB, a global biopharmaceutical company, today announced positive topline data from the BE BOLD trial assessing BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in adults with active psoriatic ...
Henkel reported solid financial performance for fiscal year 2025, with group sales reaching approximately 20.5 billion euros and organic sales growth of 0.9 percent despite geopolitical tensions and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results